Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Roots Community Health has sued 12 other firms, including GE Healthcare, CVS and Walgreens, and called for manufacturers and ...

Apple and Masimo are back in a California court this week for a bench ... the two companies in which the former alleges the ...

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...

With President-elect Donald Trump proposing tariffs as high as 60%- 100% on goods imported from China, Wall Street analysts ...

WAM ABU DHABI: Mafraq Hospital and Masimo (NASDAQ: MASI) jointly announced the hospital-wide conversion of Mafraq Hospital to Masimo rainbow SET Pulse CO-OximetryTM technology for advanced noninvasive ...

Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ETCompany ParticipantsEli Kammerman - VP of Business ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...